- Home
- PNW vs EXEL Comparison
PNW vs EXEL Comparison
Compare PNW & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNW
- EXEL
- Stock Information
- Founded
- PNW 1985
- EXEL 1994
- Country
- PNW United States
- EXEL United States
- Employees
- PNW N/A
- EXEL N/A
- Industry
- PNW Electric Utilities: Central
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PNW Utilities
- EXEL Health Care
- Exchange
- PNW Nasdaq
- EXEL Nasdaq
- Market Cap
- PNW 10.3B
- EXEL 11.1B
- IPO Year
- PNW N/A
- EXEL 2000
- Fundamental
- Price
- PNW $89.51
- EXEL $42.90
- Analyst Decision
- PNW Buy
- EXEL Buy
- Analyst Count
- PNW 13
- EXEL 24
- Target Price
- PNW $96.23
- EXEL $44.73
- AVG Volume (30 Days)
- PNW 1.6M
- EXEL 2.8M
- Earning Date
- PNW 11-03-2025
- EXEL 11-04-2025
- Dividend Yield
- PNW 4.07%
- EXEL N/A
- EPS Growth
- PNW N/A
- EXEL 53.55
- EPS
- PNW 4.92
- EXEL 2.38
- Revenue
- PNW $5,307,180,000.00
- EXEL $2,288,218,000.00
- Revenue This Year
- PNW $4.47
- EXEL $9.14
- Revenue Next Year
- PNW $4.46
- EXEL $12.51
- P/E Ratio
- PNW $18.18
- EXEL $18.15
- Revenue Growth
- PNW 5.70
- EXEL 9.93
- 52 Week Low
- PNW $81.47
- EXEL $31.90
- 52 Week High
- PNW $96.50
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- PNW 50.35
- EXEL 60.15
- Support Level
- PNW $88.24
- EXEL $41.65
- Resistance Level
- PNW $90.51
- EXEL $42.99
- Average True Range (ATR)
- PNW 1.20
- EXEL 1.25
- MACD
- PNW 0.12
- EXEL 0.07
- Stochastic Oscillator
- PNW 71.76
- EXEL 79.18
About PNW Pinnacle West Capital Corporation
Pinnacle West is a holding company whose principal subsidiary is Arizona Public Service, a vertically integrated electric utility serving approximately 1.4 million customers across a 35,000-square-mile territory in central Arizona, including the Phoenix area. APS owns or leases more than 6 gigawatts of power generation capacity, including a 29% ownership stake in one of the largest nuclear plants in the US, Palo Verde. Half of the electricity that APS supplies to customers comes from clean energy sources, including nuclear.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.